U.S. Markets closed

InVivo Therapeutics Holdings Corp. (NVIV)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.200.00 (0.00%)
At close: 4:00PM EDT
People also watch
AVXLCURONCSADXSATHX
  • Good buying interest on the bid at $2.20 this morning (over 19,000). Unless there's a sudden dump again of 100K+ shares at one time, looks like a floor is in at $2.20. A decent amount of shares on the ask at $2.25 (8,000 currently). I've thought of eating the ask myself for all of it at one time just to knock it out and se if we begin a run from it. But, I've told myself that I won't buy any trading shares for over $2.00 and I'm sticking to it for now. Especially with no new patients in nearly a month now -- I just don't understand the long delays in recruiting. We're at "peak season" for treating spinal injuries through the Summer months and just can't seem to get patients enrolled at a reasonable level. That is frustrating to me! My only guess at a reason is that NVIV enrolls two-ish at a time, then intentionally waits a month or so for next patients in an effort to space out news releases and measuring progress. Just a guess.
  • Institutional holders list is out!
    Not as bad as one might think. Does not look like Blackrock or Vanguard was dumping as many as this board would lead one to believe!
    Blackrock still holding 1.8 mil shares, Vanguard at 1.12mil shares. This is long term..
    Hold, don't Fold! Still long and strong after all of this time👊
  • FINAL PUSH, Perrin. Let's get cracking and as an investor I expect you all to be in constant contact with all of your sites and not having anyone fall through the cracks. Let's get the last three patients enrolled before the end of August if possible so this can regain some lost time. I also hope the team has been shifting their time resources to proactively work on portions that come after full enrollment. That will be an elucidating test of your management skills. How quickly can you get this to advance through all of the remaining procedural mileposts and manufacturing readiness. Your team ought to be working on those things as we speak. Any further delays after full enrollment is totally unacceptable and will show us whether you truly have what it takes to lead this company or not. To say that you receive extremely high level of compensation is an understatement. Time to prove your worth instead of appearing as the largest individual source of cash burn. Chop Chop, better earn your keep.
  • For those who post on message boards that manipulation is fiction, kindly read the attached article from today's Wall Street Journal to better understand how the vermin manipulators take advantage of average investors on a daily basis, including shareholders of NVIV. https://www.wsj.com/articles/the-wolves-of-long-island-1500506761

    The Wolves of Long Island
    The SEC does its job in taking down a pump-and-dump stock scheme.
    www.wsj.com
  • Who is still selling these shares in such large blocks? Frank? Blackstone?

    3 patients left to enroll. 3. More selling than buying at nearly all-time lows. Currently, dropped another 5% today to 2.10. MP not buying a single share with his own cash. Running out of buyers even at 2.10. Probably dropping under 2.00 again at this rate with no news today, etc. Every LT investor, at this point, has to be sorely disappointed. Many are down very, very large amounts. Baffling.
  • I can see the next corporate presentation with the statement "WE EXPECT FULL ENROLLMENT BY THE END OF THE FOURTH QUARTER" This CEO running this company is a #$%$
  • If you look at the individual trades at the close today, we have corrupt morons selling 9 shares on a down tick knocking the market cap down some $1.5 million (from $2.25 per share down to $2.20) $18 value before trade costs followed by another moron selling 1 share. How do long term shareholders seriously under water fight a war against such vermin axxholes playing with the stock. They never sleep.
  • The Perrin Report
    In the last couple of weeks, at least, we have seen some nice progress in site additions and extending out a bit further, some patient recruitments. We have also seen some positive staff additions and generally all positive pieces of news. Now what have we NOT seen in as far as new developments? What glaring deficiencies might be seen as a glaring contrast not only to the positive news but also to highlight the $40,000 per week compensation of the CEO who we would all like to know what he accomplishes to justify such excessive compensation. We STILL NEED three more patients to achieve full enrollment of this study. Withing the bounds of what is allowed, has the company checked in regularly with all of the study participants and provided the encouragement, support and inspiration to recruit qualifying patients as they present? Statistically, there should be at least 25 patients per week presenting with this type of injury. So the study sites need to not let any patients "fall through the cracks" and attain a high capture rate. There are many moving parts here, but there is one leader who has not shown much of any talent at all to be charismatic, enthusiastic, inspiring, encouraging toward all the rest of the moving parts. This same DUD appears not to have the talent to make the company's accomplishments known beyond some basic PR's released. This is significant! This person in a highly (almost obscenely) compensated position has dropped the ball in communicating to the investment community. He ought to be inspiring analysts, news outlets, financial writers and financial backers to support and get the word out. We have all heard his words, which are not often polished nor colorful, but rather bland. This same over-compensated leader has not even purchased shares in the company. He just doesn't get it. Period. He has no clue with regard to how to support the value of the company. And yes, the Board of Directors ought to be ashamed that this has gone on for this length of time.
  • What is the actual share float here with the insider, institutional, and retail holdings? Although it is considered "low" it is still too high for the current share price. Solution: Imagine if there were 6 million shares snatched up overnight by an investor (like Sabby) in a direct offering, who would intend to hold right through commercialization when the word is out about a new standard of care in the industry and everyone and their brother is buying and we're at $16 headed to a target of $30. They could sell off slowly in that range (or earlier if they are more conservative) at many times their investment and it wouldn't even affect the share price. That's what needs to happen here. Some companies have the skills to orchestrate a deal like that. It would be win-win for all, but if you are a wimp CEO, all bets are off.
  • This week we resume the Hall of Shame series. In the first two, we focused on two large population centers who have not contributed any patients, despite the unfathomable notion that there were none who presented that could have been recruited. Those were Northwestern and Mount Sinai, serving the greater Chicago and New York City metropolitan areas, respectively. Potentially a lot of SCI patients who were disenfranchised by not receiving this procedure. Now we move back to the Midwest and a lower populated area, but certainly a geography having at least an equivalent population density as some of the southern states in which there have been successful recruitments. This site was chosen due to their participation (on paper at least) from a rather early point in time.

    This site would be: Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin
    Principal Investigator: Shekar Kurpad, MD, PhD. I wonder if Dr. Kurpad could compile an accounting of how many patients have presented with a qualifying Thoracic AIS-A injury since the time this facility was "actively recruiting" and explain why there have been zero patients to date enrolled in INSPIRE. It's great that all of the sites want to be in on the action after this implant is approved. But if more of these sites had done their part during this study, this may already have received HDE approval. I don't have specific data, but the lack of any implantations from this site leaves me a bit dubious of a concerted effort by the principals to participate.
  • alright when it hits below 2 i'm loading up. only thing that scares me is if they do an offering but I have to think they are trying to hold off until enrollment is complete.
  • The bottom line here is they need to announce conversions and/or patient improvements.
  • Another uneventful week, brought to you at this point by the BOARD OF DIRECTORS.
  • Probable benefit

    This is a more complex determination than one might think superficially. We all know about the OPC that was agreed upon between Invivo and the FDA. That is certainly the most visible cue. But there are multiple other factors which we have not seen publicized because at this point it may not be deemed necessary (by Perrin, in his cough, cough, wisdom) for shareholders to be privy to all the nitty gritty details. For example, a certain percentage of SCI injuries that do not normally receive a scaffold, develop cysts which increase the pressure within the cord and put additional stress or damage onto the remaining white matter. It is reported that this can also manifest as pain in the patient. If NONE of the INSPIRE patients report such pain, then there is probable benefit from just this alone. Also, if any of the non converting patients happens to have improved bowel and bladder control, even just bladder, along with this lack of pain, then these are additional probable benefits. When all the medical records are reported, with MRI data as backup, showing positively remodeled tissue and improvements below the threshold of the (already established AIS conversions) already met OPC, it may be that every NSS recipient has demonstrated some level of probable benefit. Knock on wood, there has still been zero safety concerns to counter the list of probable benefits, so this sure does look good. It would be great to see them reach the full 20 patients as soon as possible.
  • Looks like were in for another well orchestrated week by MP. NOT. A consultant to Chairman/CEO position. Good work if you can find it
  • BORING
  • Reflecting a bit on the last 7 days, we had a very good week (although the stock price didn't react, what else is new):

    1) Two new sites: First site outside of North America, and Stanford- probably the most recognized medical establishment in the world. Many on here are not impressed with more sites but NVIV is building a reputable ecosystem and these sites are critical to that end goal. The past week two major milestones were achieved.

    2) New CMO: Dr. Toselli has a very strong background and his ties to JNJ Spine should bode well for NVIV. The leadership team is solidified as we head into the home stretch for the NSS. This is very important as partnerships, cash raises, and further R&D and clinical developments are critical to increasing shareholder value. While I am certainly in the minority in that I am not calling for Perrin's head, if Perrin did leave or was shown the door, my guess is that Toselli would be next in line if they promoted from within. So it is nice to have a next in line, so to speak.

    Looking ahead to this week, it would be great for NVIV to announce a patient enrollment. It's been a few weeks since they enrolled and with the height of the summer travel season, we should expect some progress on that front.
  • Mark Perrin, have you no shame? What you are being compensated in just one month, most Americans do not make in an entire year. With mortgages to pay and repairs and other bills, people just getting by. These same people own shares which came out of their own hard-earned money. Any you don't even buy any shares. They are given to you as options at zero risk. You even have the audacity to have your Boston area housing paid for out of the precious resources of this company. REALLY? Who pronounced you King? You really have some nerve. And you do nothing...NOTHING to support the value of the company stock. You have no clue how to support the value of a company, evidenced by actual progress which leads to continued decline of the share value. There are not that many out there with that magnitude of incompetence that can translate real success to perceived failure. You are the person who does the same thing time after time, expecting different results. Have you met with people who can write articles on InVivo's progress to help get the word out? What have you done to support the obscene level of compensation you receive all while the share price of this company continues to drop?

    Three more patients must be enrolled ASAP.
    You need to line up all the positives and illustrate these for the world to see. Stop cowering like a wimp and generate some well-deserved enthusiasm. I'm tired of seeing "death by CEO" decimate this company. If you can't channel the accomplishments made into positive trajectory then frankly you do not deserve to be CEO of the company. You have squandered so much opportunity and WASTED so much of the company finances. You yourself are the largest burner of cash, directly as well as by way of lowering the market cap. This money is neither your personal toilet paper nor dollars for you to lavish onto your significant other. You keep outdoing yourself in failure and non-performance.
  • You have to believe that there has been a conversion in one of the 5 patience enrolled since the beginning of March. I guess MP is playing by new rules and waiting for each to get to the 6 month period due to the reversion in 2 patients
  • I do believe it is impossible to overestimate this company's ability to underwhelm.